Banned Chloroform Solution Effective Against Jaw Tumors

Richard Gawel
Photo by Nephron.


Photo by Nephron.

Keratocystic odontogenic tumors (KOTs) are benign. But these locally aggressive cyst-like tumors that usually occur in the mandible tend to invade adjacent tissues and have very high recurrence rates. Carnoy’s solution (CS)—60% ethanol, 30% chloroform, and 10% acetic acid—reduces the rate of KOT occurrence in conjunction with surgery.

The Food and Drug Administration (FDA) banned the use of chloroform for compounding, though. Surgeons then adopted a modified Carnoy’s solution (MC) to treat KOT. Researchers at the University of Michigan’s department of oral and maxillofacial surgery recently studied the difference in recurrence rates between the 2 solutions.

The researchers examined 44 KOT patients who underwent surgery in conjunction with CS and 36 KOT patients treated with MC. The CS group saw a 10% recurrence rate, while the MC group saw a 35% recurrence rate. The researchers concluded, then, that the FDA could consider a clinical trial of CS in patients with KOT.

The research, “Significantly Decreased Recurrence Rates in Keratocystic Odontogenic Tumor with Simple Enucleation and Curettage Using Carnoy’s Versus Modified Carnoy’s Colution,” was published by the Journal of Oral and Maxillofacial Surgery.

Related Articles

Wisdom Teeth Stem Cells Could Treat Corneal Scarring

Shrimp Used for Better Bioluminescent Cancer Imaging

“Jaw in a Day” Replaces Fibula Free Flap Surgery